Journal article
Sorafenib in Combination With Gemcitabine in Recurrent Epithelial Ovarian Cancer A Study of the Princess Margaret Hospital Phase II Consortium
Abstract
OBJECTIVES: Antiangiogenic strategies have demonstrated efficacy in epithelial ovarian cancer (EOC). Sorafenib is a novel multitargeted kinase inhibitor with antiangiogenic activity. Gemcitabine has known activity against EOC. A phase 1 clinical trial of this combination suggested activity in ovarian cancer with no dose-limiting toxicity. This phase 2 study was designed to examine the safety and efficacy of gemcitabine and sorafenib in patients …
Authors
Welch SA; Hirte HW; Elit L; Schilder RJ; Wang L; MacAlpine K; Wright JJ; Oza AM
Journal
International Journal of Gynecological Cancer, Vol. 20, No. 5, pp. 787–793
Publisher
Elsevier
Publication Date
June 2010
DOI
10.1111/igc.0b013e3181e273a8
ISSN
1048-891X